

Supplementary Table 1. Clinicopathological characteristics of patients with biopsy-proven MAFLD

	MAFLD (n=851)
Demographics	
Age (years)	45 ± 13
Male sex, n (%)	570 (67%)
Body mass index (kg/m ²)	26.84 (24.54-29.30)
Waist circumference (cm)	92.0 (86.0-98.0)
Type 2 diabetes, n (%)	322 (38%)
Laboratory parameters	
Albumin (g/L)	45.7 (43.1-47.9)
Total bilirubin (μmol/L)	12 (9-16)
Alanine aminotransferase (U/L)	53 (31-86)
Aspartate aminotransferase (U/L)	33 (25-52)
AST/ALT ratio	0.7 (0.5-0.9)
Alkaline phosphatase (U/L)	79 (65-101)
Gamma-glutamyltransferase (U/L)	53 (34-88)
Platelet count (×10 ⁹ /L)	241 (203-282)
Glucose (mmol/L)	5.5 (5.0-6.6)
Total cholesterol (mmol/L)	5.04 (4.38-5.85)
Triglycerides (mmol/L)	1.71 (1.29-2.60)
HDL-cholesterol (mmol/L)	1.07 (0.90-1.29)
LDL-cholesterol (mmol/L)	2.94 (2.37-3.59)
PRO-C3 (ng/mL)	5.97 (4.96-9.80)
ADAPT score	3.94 (3.11-4.92)
Liver histology features	
Steatosis	1.7 ± 1.0
Ballooning	1.0 ± 0.7
Lobular inflammation	1.0 ± 0.6
Fibrosis stage	1.2 ± 1.0
NAS ≥4, n (%)	459 (54%)
Advanced fibrosis, n (%)	103 (12%)
Genotype distribution	
PNPLA3, n (%)	
CC	195 (27%)
CG	334 (47%)
GG	181 (26%)

Data are expressed as medians and interquartile ranges, means ± SDs, or proportions.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAS, NAFLD Activity Score; PRO-C3, N-terminal type III collagen propeptide.

The PNPLA3 data was available in a certain percentage of our cohort (n=710, 83.4%, Wenzhou: n=496, Hong Kong: n=214).